Uterine myomas are the most prevalent benign gynecological tumors,affecting over 70%of women[1].They are often associated with significant morbidity,including anemia and infertility.In contrast,uterine sarcomas,althou...Uterine myomas are the most prevalent benign gynecological tumors,affecting over 70%of women[1].They are often associated with significant morbidity,including anemia and infertility.In contrast,uterine sarcomas,although rare,are highly malignant,with a five-year survival rate of 50%-55%in early stages and a stark decline to 8%-12%in advanced stages[2],[3].展开更多
基金supported by the Independent Research Fund of the State Key Laboratory of Complex,Severe,and Rare Diseases(2025-I-PY-010)Beijing Municipal Natural Science Foundation(Z220013)+4 种基金the National Natural Science Foundation of China(82271656,82530054,and 82171621)the National Key R&D Program of China(2023YFC2706001)the National High Level Hospital Clinical Research Funding(2025-PUMCH-C-037 and 2022-PUMCHC-060)CAMS Initiative for Innovative Medicine(2021-I2M-1-004)Barnhart Family Distinguished Professorship from the University of Texas MD Anderson Cancer Center.
文摘Uterine myomas are the most prevalent benign gynecological tumors,affecting over 70%of women[1].They are often associated with significant morbidity,including anemia and infertility.In contrast,uterine sarcomas,although rare,are highly malignant,with a five-year survival rate of 50%-55%in early stages and a stark decline to 8%-12%in advanced stages[2],[3].
